tetano
Editor, Senior Moderator
Vaccine
. 2023 Apr 4;S0264-410X(23)00311-0.
doi: 10.1016/j.vaccine.2023.03.028. Online ahead of print.
Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens
Hyunjun Kim[SUP] 1 [/SUP], Hyun-Kyu Cho[SUP] 1 [/SUP], Yong-Myung Kang[SUP] 1 [/SUP], Mingeun Sagong[SUP] 1 [/SUP], Sungjun An[SUP] 1 [/SUP], Sungyeop Kim[SUP] 1 [/SUP], Youn-Jeong Lee[SUP] 1 [/SUP], Hyun-Mi Kang[SUP] 2 [/SUP]
Affiliations
Abstract
Worldwide, high pathogenic avian influenza viruses belonging to clades 2.3.4.4 and 2.3.2.1 have been circulating in both poultry and wild birds. Since 2018, Korea has built a national antigen bank to ensure preparedness in an emergency. In this study, we developed a bivalent vaccine candidate containing antigens derived from two reassortant KA435/2.3.2.1d and H35/2.3.4.4b strains for Korean national antigen bank. We evaluated its immunogenicity and protective efficacy in specific pathogen free chickens. The two vaccine strains, rgKA435-H9N2 PB2/2.3.2.1d and rgH35/2.3.4.4b, both of which were generated successfully by reverse genetics, were highly immunogenic (titres of haemagglutination inhibition: 8.3 and 8.4 log[SUB]2[/SUB], respectively) and showed good protective efficacy (100 and 147 50% protective dose, respectively) against lethal challenge with wild-type virus when delivered as a 1:1 mixture. Notably, the vaccine provided complete protection against viral shedding at a full dose (512 HAU) and a 1/10 dose (51.2 HAU), with no clinical signs, after challenge with H35/2.3.4.4b. The bivalent vaccine developed in this study may reduce the cost of vaccine production and could be used as a H5 subtype avian influenza vaccine candidate against two clades simultaneously.
Keywords: Antigen bank; Avian influenza; Bivalent vaccine; H5; Protective efficacy.
. 2023 Apr 4;S0264-410X(23)00311-0.
doi: 10.1016/j.vaccine.2023.03.028. Online ahead of print.
Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens
Hyunjun Kim[SUP] 1 [/SUP], Hyun-Kyu Cho[SUP] 1 [/SUP], Yong-Myung Kang[SUP] 1 [/SUP], Mingeun Sagong[SUP] 1 [/SUP], Sungjun An[SUP] 1 [/SUP], Sungyeop Kim[SUP] 1 [/SUP], Youn-Jeong Lee[SUP] 1 [/SUP], Hyun-Mi Kang[SUP] 2 [/SUP]
Affiliations
- PMID: 37024409
- DOI: 10.1016/j.vaccine.2023.03.028
Abstract
Worldwide, high pathogenic avian influenza viruses belonging to clades 2.3.4.4 and 2.3.2.1 have been circulating in both poultry and wild birds. Since 2018, Korea has built a national antigen bank to ensure preparedness in an emergency. In this study, we developed a bivalent vaccine candidate containing antigens derived from two reassortant KA435/2.3.2.1d and H35/2.3.4.4b strains for Korean national antigen bank. We evaluated its immunogenicity and protective efficacy in specific pathogen free chickens. The two vaccine strains, rgKA435-H9N2 PB2/2.3.2.1d and rgH35/2.3.4.4b, both of which were generated successfully by reverse genetics, were highly immunogenic (titres of haemagglutination inhibition: 8.3 and 8.4 log[SUB]2[/SUB], respectively) and showed good protective efficacy (100 and 147 50% protective dose, respectively) against lethal challenge with wild-type virus when delivered as a 1:1 mixture. Notably, the vaccine provided complete protection against viral shedding at a full dose (512 HAU) and a 1/10 dose (51.2 HAU), with no clinical signs, after challenge with H35/2.3.4.4b. The bivalent vaccine developed in this study may reduce the cost of vaccine production and could be used as a H5 subtype avian influenza vaccine candidate against two clades simultaneously.
Keywords: Antigen bank; Avian influenza; Bivalent vaccine; H5; Protective efficacy.